Pre Clinical Research

What do men do if they are deemed ineligible for the PSMA treatments available through ProsTIC?

The research teams at ProsTIC are tackling this question, with innovative pre-clinical research programs.

At ProsTIC, we brought together world-class researchers in prostate cancer and immunotherapy, to establish evidence that immunotherapy can be effective in treating prostate cancer. The cancer researchers have established human prostate tumours so that they grow in the laboratory outside the patient and have tested an immunotherapy product known as ‘CAR T cell therapy’ that has already been approved by regulatory authorities in Australia

Our results show that CAR T cell therapy eradicates tumours from some patients and are beginning to understand which subtype of prostate tumour will be most responsive. This is important information as we are poised to go to the clinic, and test this new immunotherapy on patients in clinical trials; but it is always better if we can identify the patients most likely to respond.

There is an overwhelming sense of excitement and urgency in this project as we have an approved therapy that can move into clinical trial in a very short time.

Watch this space! Now watch this video of a tumour being killed by CAR-T cells.  This video was created by our talented young research team.

Dr Laura Porter
Monash Biomedicine Discovery Institute

Dr Joe Zhu
Peter MacCallum Cancer Centre

Dr Natalie Lister
Monash Biomedicine Discovery Institute

Professor Phil Darcy
Peter MacCallum Cancer Centre

Associate Professor Renea Taylor
Monash Biomedicine Discovery Institute
Peter MacCallum Cancer Centre

Associate Professor Paul Neeson
Peter MacCallum Cancer Centre

Professor Gail Risbridger
Monash Biomedicine Discovery Institute
Peter MacCallum Cancer Centre

Professor Joe Trapani
Peter MacCallum Cancer Centre